文献速递心力衰竭与心肌病

恩格列净对射血分数轻度降低心力衰竭患者峰值摄氧量的影响:一项随机对照试验

[Impact of empagliflozin on peak oxygen uptake in HFmrEF patients: a randomized controlled trial].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2022-01-01

该随机对照试验纳入112例HFmrEF患者,随机分为恩格列净组(57例,在常规治疗基础上加用恩格列净10 mg每日1次口服)和常规治疗组(55例)。治疗6个月后,恩格列净组VO2peak显著高于常规治疗组(P=0.023),且VE/VCO2斜率、摄氧效率斜率、NT-proBNP、6分钟步行距离和KCCQ评分均显著改善。结论提示恩格列净可改善HFmrEF患者的VO2peak。

要点

  • 恩格列净组治疗6个月后VO2peak显著高于常规治疗组(P=0.023)。
  • 恩格列净组VE/VCO2斜率更低、摄氧效率斜率更高(P分别为0.034和0.038)。
  • 恩格列净组NT-proBNP、6分钟步行距离和KCCQ评分均显著优于常规治疗组。

核心结论

  • 恩格列净可改善HFmrEF患者的VO2peak。

研究设计与样本

  • 该研究为随机对照试验,连续入选2019年9月至2020年10月就诊于中日友好医院心内科的HFmrEF患者。
  • 最终入选112例患者,年龄69(57,78)岁,男性84例(75.0%),常规治疗组55例,恩格列净组57例。
  • 采用随机数字表法分组,恩格列净组在常规治疗基础上加用恩格列净10 mg每日1次口服。

主要发现

  • 治疗后6个月,恩格列净组VO2peak高于常规治疗组(P=0.023)。
  • 恩格列净组二氧化碳通气当量斜率低于常规治疗组(P=0.034),摄氧效率斜率高于常规治疗组(P=0.038)。
  • 恩格列净组NT-proBNP水平低于常规治疗组(P=0.020),6分钟步行距离大于常规治疗组(P=0.037),KCCQ评分高于常规治疗组(P=0.048)。
  • 运动振荡通气两组各1例,差异无统计学意义(P>0.05)。

关键数值与推荐

  • 主要终点为治疗后6个月VO2peak,次要终点包括CPET其他参数、6分钟步行距离、NT-proBNP水平和KCCQ评分。
  • 恩格列净用法为10 mg,每日1次,口服。

临床怎么用

  • 对于HFmrEF患者,在指南规范化药物治疗基础上可考虑加用恩格列净10 mg每日1次,以改善峰值摄氧量及心肺运动参数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the impact of empagliflozin on peak oxygen uptake (VO2peak) in patients with heart failure with mildly reduced ejection fraction (HFmrEF). Methods: In this randomized controlled trial, consecutive HFmrEF patients admitted to the Department of Cardiology of China-Japan Friendship Hospital from September 2019 to October 2020 were screened, and randomly assigned to empagliflozin group (EG) or conventional group (CG) using a random number table. The enrolled patients were treated according to the guidelines, and patients in the empagliflozin group received additional empagliflozin (10 mg, once a day, orally) on top of the conventional treatment. The primary end points were VO2peak at 6 months after treatment, and the secondary end points included other parameters of cardiopulmonary exercise test (CPET), 6-minute walking distance, N-terminal B-type pro-natriuretic peptide (NT-proBNP) level, and Kansas City Cardiomyopathy Questionnaire (KCCQ) score. Results: A total of 112 patients were included (mean age 69 (57, 78) years, 84 male (75.0%)). There were 55 cases in CG group and 57 cases in EG group. There were no significant differences in baseline data including age, sex, body mass index, left ventricular ejection fraction, systolic blood pressure, heart rate, estimated glomerular filtration rate, glycosylated hemoglobin, hemoglobin, NT-proBNP, daily dose of tolasemi, combined medication, CPET parameters, the proportion of New York Heart Association heart function Ⅲ/Ⅳ, history of coronary heart disease, history of hypertension, history of diabetes (all P>0.05). At 6 months after treatment, VO2peak was significantly higher in EG group than in CG group(P=0.023). VE/VCO2 slope was significantly lower in EG group than in CG group(P=0.034). Oxygen uptake efficiency slope was significantly higher in EG group than in CG group(P=0.038). The level of NT-proBNP was significantly lower in EG group than in CG group(P=0.020). Six-minute walking distance was significantly higher in EG group than in CG group(P=0.037). KCCQ score was significantly higher in EG group than in CG group(P=0.048). Exercise oscillatory ventilation decreased in both groups (1 case in each group, P>0.05). Conclusion: Empagliflozin can significantly improve VO2peak in patients with HFmrEF. 目的: 探讨恩格列净对射血分数轻度降低的心力衰竭(HFmrEF)患者峰值摄氧量(VO2peak)的影响。 方法: 该研究为随机对照试验。连续入选2019年9月至2020年10月就诊于中日友好医院心内科的HFmrEF患者,采集患者的基线临床资料。采用随机数字表法将患者分为恩格列净组和常规治疗组。根据指南对入选患者进行规范化药物调整,恩格列净组在常规治疗的基础上加用恩格列净(10 mg,每日1次,口服)。主要终点为治疗后6个月患者的VO2peak,次要终点包括心肺运动试验(CPET)的其他参数、6 min步行距离、N末端B型利钠肽原(NT-proBNP)水平以及堪萨斯城心肌病调查问卷(KCCQ)评分。 结果: 最终入选患者112例,年龄69(57,78)岁,男性84例(75.0%)。其中常规治疗组55例,恩格列净组57例,两组间年龄、性别、体重指数、左心室射血分数、收缩压、心率、估算的肾小球滤过率、糖化血红蛋白、血红蛋白、NT-proBNP、托拉塞米日剂量、合并用药、CPET各参数以及纽约心脏协会心功能Ⅲ/Ⅳ级、有冠心病病史、有高血压病史、有糖尿病病史患者所占比例差异均无统计学意义(P均>0.05)。治疗后6个月,恩格列净组患者的VO2peak高于常规治疗组(P=0.023),二氧化碳通气当量斜率水平低于常规治疗组(P=0.034),摄氧效率斜率高于常规治疗组(P=0.038);NT-proBNP水平低于常规治疗组(P=0.020),6 min步行距离大于常规治疗组(P=0.037),KCCQ评分高于常规治疗组(P=0.048)。 结论: 恩格列净可改善HFmrEF患者的VO2peak。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wu WJ, Zhang SY, Liu C, et al. [Impact of empagliflozin on peak oxygen uptake in HFmrEF patients: a randomized controlled trial]. Zhonghua Xin Xue Guan Bing Za Zhi. 2022. PMID: 35856224. doi:10.3760/cma.j.cn112148-20220120-00059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。